|
|
Line 493: |
Line 493: |
| ! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}} | | ! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}} |
| |- | | |- |
| | rowspan="30" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Kidney diseases | | | rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Kidney diseases |
| | style="padding: 5px 5px; background: #F5F5F5;" |Electrolyte imbalance (LP) | | | style="padding: 5px 5px; background: #F5F5F5;" |Electrolyte imbalance (LP) |
| | style="padding: 5px 5px; background: #F5F5F5;" | | | | style="padding: 5px 5px; background: #F5F5F5;" | |
Line 670: |
Line 670: |
| | style="padding: 5px 5px; background: #F5F5F5;" | | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| |- | | |- |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Beta-2 microglobulin related amyloidosis
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |Gelsolin related amyloidosis
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |- | | |- |
| | style="padding: 5px 5px; background: #F5F5F5;" | | | | style="padding: 5px 5px; background: #F5F5F5;" | |
Line 728: |
Line 679: |
| | style="padding: 5px 5px; background: #F5F5F5;" | | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| |- | | |- |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |-
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" |
| |
| |- | | |- |
| | style="padding: 5px 5px; background: #F5F5F5;" | | | | style="padding: 5px 5px; background: #F5F5F5;" | |
System leader: Maneesha Nandimandalam, MD
List of Chapters Requiring Content
Category
|
Chapters that need content
|
Assignment Status
|
Scholar's name
|
Coach name
|
Completion Status
|
Review status
|
Reviewer name
|
Kidney diseases
|
|
|
|
|
|
|
|
- Abderhalden-Kaufmann-Lignac syndrome
|
|
|
|
|
|
|
|
Assigned
|
Shakiba
|
Elsaiey, Ahmed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Continuous veno-venous hemofiltration
|
|
|
|
|
|
|
- Contrast-induced acute kidney injury
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Fibrillary immunotactoid glomerulopathy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- HIV associated nephropathy
|
Assigned
|
Shakiba
|
Elsaiey,Ahmed
|
Completed
|
|
|
|
Assigned
|
Nasrin
|
Elsaiey,Ahmed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Multicystic dysplastic kidney
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assingned
|
Ayesha FJ
|
Sogand
|
|
|
|
|
Assingned
|
Ayesha FJ,
|
Sogand
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In progress chapters
Category
|
Chapters that need content
|
Assignment Status
|
Scholar's name
|
Coach name
|
Completion Status
|
Review status
|
Reviewer name
|
Kidney diseases
|
Cardiorenal syndrome
|
Assigned
|
Dina
|
Huda
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Completed chapters
Category
|
Chapters that need content
|
Assignment Status
|
Scholar's name
|
Coach name
|
Completion Status
|
Review status
|
Reviewer name
|
Kidney diseases
|
Electrolyte imbalance (LP)
|
|
|
|
|
|
|
Hyponatremia
|
|
|
|
|
|
|
Hypernatremia
|
|
|
|
|
|
|
Hypokalemia
|
|
|
|
|
|
|
Hyperkalemia
|
|
|
|
|
|
|
Hypocalcemia
|
|
|
|
|
|
|
Hypercalcemia
|
|
|
|
|
|
|
Glomerular Disease(LP)
|
|
|
|
|
|
|
Lupus Nephritis
|
|
|
|
|
|
|
Rapidly progressive glomerulonephritis
|
|
|
|
|
|
|
Membranous glomerulonephritis
|
|
|
|
|
|
|
Membranoproliferative glomerulonephritis
|
|
|
|
|
|
|
IgA nephropathy
|
|
|
|
|
|
|
Goodpastures syndrome
|
|
|
|
|
|
|
Amyloidosis (LP)
|
|
|
|
|
|
|
Primary amyloidosis
|
|
|
|
|
|
|
Secondary amyloidosis
|
|
|
|
|
|
|
Familial amyloidosis
|
|
|
|
|
|
|
Wild-type(senile) amyloidosis
|
|
|
|
|
|
|
Cardiac amyloidosis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|